Wei-Che Ko

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wei-Che Ko sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Wei-Che Ko: 1 sponsored US clinical trial, 1 recruiting.

Wei-Che Ko sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Allergic Contact Dermatitis, with 1 trials.

Mid-pack sponsor footprint

Wei-Che Ko is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING Phase 2

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

NCT05535738

Phase Distribution

PhaseTrial count
Phase 2 1

Therapeutic Areas

Allergic Contact Dermatitis 1
Skin Inflammation 1

What is open in the Wei-Che Ko pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Allergic Contact Dermatitis (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wei-Che Ko: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Wei-Che Ko sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Wei-Che Ko1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Wei-Che Ko sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wei-Che Ko sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Wei-Che Ko page

1 registered trials is a research-attention snapshot, not an endorsement of Wei-Che Ko or any single study.

  • 1 of Wei-Che Ko's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Allergic Contact Dermatitis is the condition Wei-Che Ko studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Allergic Contact Dermatitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Wei-Che Ko pipeline card: 1 registered trials from official public datasets.Report a data error.